Mereo BioPharma (MREO) Gains from Sales and Divestitures (2023 - 2024)

Mereo BioPharma (MREO) reported Gains from Sales and Divestitures of $1.3 million for Q4 2024, up 166.89% year-over-year from $501380.0 in Q1 2024, and little changed quarter-over-quarter from $1.3 million in Q3 2024.

Mereo BioPharma (MREO) Gains from Sales and Divestitures (2023 - 2024) Analysis & Trends

Mereo BioPharma (MREO) has 2 years of Gains from Sales and Divestitures data on file, last reported at $1.3 million in Q4 2024.

  • Gains from Sales and Divestitures for Q4 2024 came in at $1.3 million, up 166.89% year-over-year; the trailing twelve-month figure through Dec 2024 was $1.3 million (up 166.89% YoY), and the FY2024 annual result was $1.3 million, up 166.89% from the prior year.
  • Gains from Sales and Divestitures was little changed at $1.3 million in Q4 2024 per MREO's latest filing, from $1.3 million in the prior quarter.
  • Over five years, Gains from Sales and Divestitures peaked at $1.3 million in Q3 2024 and troughed at $142583.0 in Q1 2024.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn -
7 Psyence Biomedical 212.16 Bn 212.16 Bn -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn
9 Abivax 91.96 Bn 91.96 Bn -
10 Mereo BioPharma 252.49 Mn 252.49 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2024 1.34 Mn
Dec 31, 2024 1.34 Mn
Sep 30, 2024 1.34 Mn
Sep 30, 2024 1.34 Mn
Jun 30, 2024 802,890.00
Jun 30, 2024 802,890.00
Mar 31, 2024 142,583.00
Mar 31, 2024 142,583.00
Dec 31, 2023 501,380.00
Dec 31, 2023 501,380.00